Cystic Fibrosis (CF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Cystic fibrosis (CF), a single-gene disease with autosomal recessive inheritance, is caused by a mutation in the CF gene aptly named the CFTR protein. The CFTR protein creates a chloride channel, which is essential for efficient mucus transport. Mutations in CFTR disrupt chloride secretion, water transport, and sodium reabsorption, leading to mucus hyper concentration and decreased mucociliary clearance. Dehydrated mucus secretions cause endobronchial infection with a narrow spectrum of distinctive bacteria and exaggerated inflammatory response, which results in the development of severe bronchiectasis rather than fibrosis and, eventually, respiratory failure. The first signs of CF are gastrointestinal and nutritional disorders.
- According to Cystic Fibrosis Foundation, about ~38,000 Americans, ~5,200 Canadians, and ~27,000 Europeans are living with CF. The disease is less common in other regions of the world.
Thelansis’s “Cystic Fibrosis (CF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cystic Fibrosis (CF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Cystic Fibrosis (CF) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Cystic Fibrosis (CF) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment